Products Categories
| CAS No.: | 7487-88-9 |
|---|---|
| Name: | Magnesium sulfate |
| Molecular Structure: | |
|
|
|
| Formula: | MgSO4 |
| Molecular Weight: | 120.369 |
| Synonyms: | Arrosalt2327;Epsom salt;Epsom salts;MG-OK 100;MN 30;Magnesium sulfate (1:1);Mg-OK;OT-S;OT-S (drying agent);Sulfuric acid magnesium salt;Sulfuric acid, magnesium salt (1:1);TomixOT;Magnesium sulfate anhydrous;Magnesium sulfate;Magnesium Sulphate; |
| EINECS: | 231-298-2 |
| Density: | 2.66 g/cm3 |
| Melting Point: | 1124 °C |
| Boiling Point: | 330 °C at 760 mmHg |
| Solubility: | H2O: 1 M at 20 °C |
| Appearance: | White crystalline powder |
| Hazard Symbols: |
 Xi
|
| Risk Codes: | 36/37/38 |
| Safety: | 22-24/25-36-26 |
| PSA: | 88.64000 |
| LogP: | -0.25720 |
- 81281-59-67-Benzylideneaminotheophylline
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 852475-26-4MC1568
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 894852-01-87-BROMO-2,2-DIMETHYL-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE
- 90221-55-92-bromo-5-methylbenzaldehyde
- 885590-99-82,3-DIFLUORO-4-IODOBENZALDEHYDE
- 97730-31-9(S)-4'-(2-Methylbutyl)Biphenyl-4-Carbonitrile
| Conditions | Yield |
|---|---|
| 70 °C; 1-2. step of Mg-S-I water splitting cycle; | A 100% B 100% |
| Conditions | Yield |
|---|---|
| In solid byproducts: H2O; mixt. heating in derivatograph in Pt crucible at 10 K/min in air up to 850°C; TG, DTG, DTA; | A 78.7% B n/a |
| In solid byproducts: H2O; mixt. heating in derivatograph in Pt crucible at 10 K/min in air up to 1000°C; TG, DTG, DTA; | A 47.2% B n/a |
| Conditions | Yield |
|---|---|
| In solid byproducts: H2O; mixt. heating in derivatograph in Pt crucible at 10 K/min in air up to 1000°C; TG, DTG, DTA; | A 73.8% B n/a |
| Conditions | Yield |
|---|---|
| In water byproducts: CaSO4; aq. suspension of dolomite was treated with SO2-containing gas with formation of sol. sulfites, air was passed through the soln. forming the sulfates, Ca was removed as CaSO4;; MgSO4-soln. obtained;; |
| Conditions | Yield |
|---|---|
| In solid heating at 600-900 °C; X-ray diffraction; |
| Conditions | Yield |
|---|---|
| In sulfuric acid dolomite was dissolved in H2SO4;; MgSO4 was not isolated;; | |
| In sulfuric acid dolomite was dissolved in H2SO4;; MgSO4 was not isolated;; |
| Conditions | Yield |
|---|---|
| In water byproducts: CaSO4; aq. suspension of dolomite was treated with NaHSO3-soln. at elevated temp., air was passed through the soln.;; MgSO4-soln. obtained;; |
| Conditions | Yield |
|---|---|
| In water dolomite was dissolved in NaHSO4-soln.;; MgSO4 was not isolated;; |
| Conditions | Yield |
|---|---|
| In water byproducts: CaSO4; calcined dolomite was heated with (NH4)2SO4-soln., Mg was dissolved as MgSO4 while Ca remained as CaSO4 in the residue;; MgSO4 was not isolated;; | |
| In water byproducts: CaSO4; calcined dolomite was heated with (NH4)2SO4-soln., Mg was dissolved as MgSO4 while Ca remained as CaSO4 in the residue;; MgSO4 was not isolated;; |
- 7487-88-9
magnesium sulfate
| Conditions | Yield |
|---|---|
| byproducts: H2O; thermal dehydration; | |
| With sulfuric acid In neat (no solvent) byproducts: H2O; heating with H2SO4 to avoid decompn., removal of the excess of H2SO4 at 600 to 700°C;; | |
| With sulfuric acid In neat (no solvent) byproducts: H2O; heating with H2SO4 to avoid decompn.;; |
What can I do for you?
Get Best Price
Specification
The IUPAC name of Magnesium sulphate is magnesium sulfate. With the CAS registry number 7487-88-9, it is also named as Sulfuric acid, magnesium salt (1:1). The product's categories are Inorganics; Drying Agents; Analytical Reagents; Special Applications; Essential Chemicals; Reagent Plus; Routine Reagents; BiochemicalsSynthetic Reagents; Magnesium; Molecular Biology; Molecular Biology Reagents; Inorganic Salts; Magnesium Salts; MagnesiumMetal and Ceramic Science; Salts; Synthetic Reagents; Complexometric Concentrates (IDRANAL)Titration; Concentrates; Salt Concentrates; Titration; G - M; Salt Solutions; Volumetric Solutions; BioUltraProtein Structural Analysis; DNA & RNA Purification; etc., and the other registry number is 139939-75-6. Besides, it is white crystalline powder, which should be stored in sealed, cool and dry place. In addition, its molecular formula is MgSO4 and molecular weight is 120.36.
The other characteristics of this product can be summarized as: (1)EINECS: 231-298-2; (2)ACD/LogP: -1.03; (3)# of Rule of 5 Violations: 0; (4)ACD/LogD (pH 5.5): -5.53; (5)ACD/LogD (pH 7.4): -5.53; (6)ACD/BCF (pH 5.5): 1; (7)ACD/BCF (pH 7.4): 1; (8)#H bond acceptors: 4; (9)#H bond donors: 2; (10)#Freely Rotating Bonds: 0; (11)Polar Surface Area: 82.98 Å2; (12)Density: 2.66 g/cm3; (13)Melting Point: 1124 °C; (14)solubility: H2O: 1 M at 20 °C; (15)Enthalpy of Vaporization: 62.94 kJ/mol; (16)Boiling Point: 330 °C at 760 mmHg; (17)Vapour Pressure: 3.35E-05 mmHg at 25 °C.
Preparation of Magnesium sulphate: this chemical can be prepared by the recrystallization of industrial magnesium sulfate.
.gif){kind=small}
Uses of Magnesium sulphate: this chemical is used to correct magnesium deficiency in soil in agriculture and gardening. It can also be used in organic synthesis as a desiccant due to its affinity for water. Additionally, it is used in bath salts. And it is also absorbed into the skin, reducing inflammation. It is commonly used as a saline laxative. Furthermore, it can be used to treat eclampsia in pregnant women. It can be used as the electrolyte to prepare copper sulfate:
Cu + MgSO4 + 2 H2O → H2 + CuSO4 + Mg(OH)2
When you are using this chemical, please be cautious about it as the following: it is irritating to eyes, respiratory system and skin. Please do not breathe dust. And in case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Moreover, you should wear suitable protective clothing to avoid contact with skin and eyes.
People can use the following data to convert to the molecule structure.
(1)Canonical SMILES: [O-]S(=O)(=O)[O-].[Mg+2]
(2)InChI: InChI=1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
(3)InChIKey: CSNNHWWHGAXBCP-UHFFFAOYSA-L
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| cat | LDLo | subcutaneous | 1gm/kg (1000mg/kg) | BEHAVIORAL: GENERAL ANESTHETIC | American Journal of Physiology. Vol. 14, Pg. 366, 1905. |
| dog | LDLo | intraperitoneal | 1200mg/kg (1200mg/kg) | "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1364, 1935. | |
| dog | LDLo | subcutaneous | 1500mg/kg (1500mg/kg) | "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1364, 1935. | |
| guinea pig | LDLo | subcutaneous | 1800mg/kg (1800mg/kg) | BEHAVIORAL: GENERAL ANESTHETIC BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | American Journal of Physiology. Vol. 14, Pg. 366, 1905. |
| man | TDLo | oral | 428mg/kg (428mg/kg) | BEHAVIORAL: MUSCLE WEAKNESS LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Japanese Journal of Toxicology. Vol. 2, Pg. 285, 1989. |
| mouse | LD50 | intraperitoneal | 1029mg/kg (1029mg/kg) | Farmakologiya i Toksikologiya Vol. 10, Pg. 107, 1975. | |
| mouse | LD50 | subcutaneous | 645mg/kg (645mg/kg) | Zhongguo Yaoli Xuebao. Acta Pharmacologica Sinica. Chinese Journal of Pharmacology. Vol. 7, Pg. 178, 1986. | |
| mouse | LDLo | intravenous | 48mg/kg (48mg/kg) | Toxicology and Applied Pharmacology. Vol. 4, Pg. 492, 1962. | |
| mouse | LDLo | oral | 5gm/kg (5000mg/kg) | "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1364, 1935. | |
| rabbit | LDLo | oral | 3gm/kg (3000mg/kg) | "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1364, 1935. | |
| rabbit | LDLo | subcutaneous | 1750mg/kg (1750mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | American Journal of Physiology. Vol. 14, Pg. 366, 1905. |
| rat | LD50 | subcutaneous | 1200mg/kg (1200mg/kg) | Neuroscience Letters. Vol. 117, Pg. 207, 1990. | |
| women | LDLo | intravenous | 80mg/kg/2M-I (80mg/kg) | CARDIAC: OTHER CHANGES LUNGS, THORAX, OR RESPIRATION: CYANOSIS | South African Medical Journal. Vol. 67, Pg. 145, 1985. |
| women | TDLo | intraspinal | 20mg/kg (20mg/kg) | PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITH APPROPRIATE ANESTHESIA | South African Medical Journal. Vol. 68, Pg. 367, 1985. |
| women | TDLo | oral | 351mg/kg (351mg/kg) | BEHAVIORAL: MUSCLE WEAKNESS CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) BLOOD: "CHANGES IN SERUM COMPOSITION (E.G., TP, BILIRUBIN, CHOLESTEROL)" | Journal of Toxicology, Clinical Toxicology. Vol. 34, Pg. 735, 1996. |